To the editor:

In a recent issue of *Eurosurveillance*, Betsch argued that vaccination of healthcare workers (HCWs) will prevent transmission of pathogens from HCWs to patients and that HCW vaccination should be encouraged by correcting skewed impressions of risk and by an appeal to altruistic or ‘pro-social’ motivation [1]. Using hepatitis B and influenza vaccines as examples, Betsch noted there appeared to be less resistance to hepatitis B than to influenza vaccination, quoting a study of German medical students showing 87% vaccination coverage against hepatitis B compared with 35% against influenza [2].

While there are a number of accepted reasons that HCWs refuse vaccination [3], part of the explanation for this observation may also be the different perception of these two vaccines.

In the early trials of hepatitis B vaccine targeting at-risk seronegative human immunodeficiency virus (HIV) infected men, hepatitis B vaccine provided 92% protection [4]. This level of protection has been repeatedly confirmed and population-based vaccination programmes in the past 20 years have reduced the burden of hepatitis B in many previously highly endemic countries [5,6].

Inactivated influenza vaccines are less effective than hepatitis B vaccines. Evidence from contemporary meta-analyses of randomised controlled trials suggest point estimates of efficacy of influenza vaccines of 59% [7] and 52% to 65%, with the latter range depending on the degree of match between the circulating and vaccine strains [8]. These trials were performed in healthy adults, who would be generally representative of HCWs. A meta-analysis of observational case–control studies in older people – who are targeted for influenza vaccination in most countries with publicly funded programmes – suggested that inactivated influenza vaccines were of the order of 50% effective [9].

Annual vaccination is needed to provide immunity against influenza, but because the influenza vaccine is only partially effective, immunity will only be partial. Only three or four primary doses of hepatitis B vaccine are needed to confer probable lifelong immunity in most recipients [10].

Vaccinating HCW against hepatitis B will provide very good protection for both the HCW and subsequently the HCW’s patients, with systems usually in place to identify the small proportion of people who fail to respond to vaccine. Unfortunately, we cannot reach the same conclusion about vaccinating HCW against influenza when the aim of vaccination is to protect patients from hospital-acquired influenza. Firstly, given that most HCWs can be considered as healthy working adults, a group for which the influenza vaccine has been shown to be only moderately effective, influenza vaccination does not guarantee immunity against influenza for the HCW [7,8]. Secondly, HCWs are not the only source of influenza for hospitalised patients. In a review of 28 published studies of influenza outbreaks in hospitals, HCWs were assessed as the outbreak source in 10 (35%) outbreaks, patients in six (22%) outbreaks and friends and visitors in six (22%) outbreaks. No source was identified for the remaining six (22%) outbreaks [11]. Lastly, there are no good quality studies to suggest vaccinating HCWs against influenza protects patients in hospitals from laboratory-confirmed influenza. Existing evidence on protection of patients is derived from cluster randomised trials or observational studies in nursing homes and is based on non-specific outcomes, such as prevention of all-cause mortality [12]. Non-specific outcomes have been shown to produce biased estimates of direct influenza vaccine effectiveness in this patient group [13]. Such biases may well be amplified when considering indirect protection of older patients through incomplete HCW vaccination.

Despite these shortcomings, however, one can mount an ethical argument for vaccinating HCWs who care for patients. Firstly, with only occasional exceptions, inactivated influenza vaccines are safe. Secondly, influenza vaccines may protect HCWs, their families and patients from influenza. Thirdly, HCWs have a duty of care to protect their patients. The ethical argument is
stronger when made in the context of a hospital respiratory infection prevention programme, which may also include respiratory precautions and appropriate sickness absence behaviour.

However, it may be more difficult to make an ethical argument for HCWs who do not have direct patient contact when vaccination would only be done to protect the HCW. In this case, encouraging or mandating vaccination may compromise the ethical principles of autonomy and bodily integrity. In this context, vaccination of HCWs is restricted to those with patient contact in the United Kingdom (UK) [14]. However, differential treatment of HCWs (with and without direct patient contact) can also introduce an ethical dilemma. Aristotle’s principle of justice maintains that equals should be treated equally.

The evidence for vaccinating populations against hepatitis B is strong and there are vaccination programmes in many endemic and non-endemic countries. On the other hand, while there is good evidence that influenza vaccines provide modest protection to recipients in most years, there is no good evidence that vaccinating HCWs in hospitals will protect their patients from influenza. It has been frequently argued that the ethical reasons for vaccinating HCWs against influenza to protect their patients outweigh the lack of evidence of benefit. Yet the ethical argument is not straightforward, with different arguments able to be advanced for HCWs with and without direct patient contact. Not all jurisdictions adopt the same approach to HCW influenza vaccination as the UK. It is hardly surprising then that the debate continues. What remains surprising is some of the ethical and evidential arguments used in the debate.

Acknowledgements

I thank Richard Pebody for valuable comments and advice.

Conflict of interest

None declared.

Authors’ contributions

HK is the sole author and takes responsibility for all views expressed.

References


